The problem, measured the way clinicians measure it
The Hamilton Depression Rating Scale (HAM-D), published 1960 by Max Hamilton, remains the primary endpoint in FDA-registered antidepressant trials. Sixty-five years of clinical, regulatory, and reimbursement infrastructure rests on it.
Most companies calling themselves "AI for mental health" do not speak this language. They speak mood scores and wellness streaks. None of those clear an FDA primary endpoint. None of those reimburse.
We speak HAM-D. Because our architecture is built on neurochemistry, not vibes.
Our proposal
Most drug-discovery synthetic data is molecular. Almost none of it is behavioral, chemistry-labeled, at scale. The pharma industry does not have a clean source of human-NPC interaction data anchored to neurochemical state.
Players interact with NPCs in Chronicles of Apocalyptica. Every NPC carries a 10D neurochemical profile (the substrate patented in 63/939,190). Every interaction shifts that profile. Every shift is logged with an ALCOA+ audit chain. Per-call SHA-256, reproducible, regulator-grade.
Entertainment subscription. Behavioral-data licensing to pharma.
Each arm covers different cost lines. Neither depends on the other to make sense.
Synthetic-data generation for pharma requires no FDA approval. The bar is defensibility: justify the data selection, show how it reflects real-world neurochemistry. We can. The chemistry profile our players generate is the same neurochemistry the regulator already measures with HAM-D.
Scyla. The glucose pathway. Proof we code biology.
glycolysis.sy.Scyla is our compiler. Rust. Biology-native opcodes. CUDA-backed. It compiles .sy source files that describe biology as code, not as text a model has memorized.
The 10-step glycolytic pathway. The insulin signaling cascade. GLUT4 translocation. Every enzyme tagged with its accession number and gene symbol. Every step cited to primary literature: Lehninger 2021 · Saltiel & Kahn, Nature 2001 · Huang & Czech, Cell Metab 2007. Patent pending 64/034,536.
ATP yield, enzyme kinetics, regulatory feedback. Real math runs over the pathway. Not approximated by a language model that has read about glycolysis. Computed from the pathway itself.
Once glycolysis is code, every tissue that uses glucose can import it. A cardiomyocyte module imports it one way. A skeletal-muscle module imports it differently. A hepatocyte module reverses it. Heart, muscle, organ-in-failure — simulated as a system, not a story.
Mayo Clinic Berg Innovation Exchange · Waypoints Program
Your neurochemical cascade architecture for AI language models is a very interesting and differentiated approach, and we appreciate the level of thought and development behind it.
Based on what you shared, we think you could be a strong candidate for our Waypoints Program. Our next application window is expected to open on June 21. David Kim · Business Analyst · Mayo Clinic Berg Innovation Exchange
The proof-of-concept demo lands eighteen days before the Mayo application window opens. We walk into the Mayo application with a working demo in hand.
Training data for the AI
The open internet is scraped. The lawsuits are pending. Clinical-grade datasets cost millions. Most AI companies do not have a clean answer for what they train on after 2026.
The flywheel. Players play. The product generates chemistry-tagged data. That data trains the next AETHER. Better AETHER, better NPCs. Better NPCs, more players. Every revenue arm produces training data for the next.
Chronicles of Apocalyptica
Seven interconnected sagas of authored canon, written over years, in a single coherent cosmology. This is not procedurally generated. It is authored.
The four patents protect the substrate. The 4M+ words of authored canon protect the surface. A language model cannot generate this. A studio of writers would need years to catch up.
The data arm has a future because the gaming arm has a world worth staying in.
The offer